Image

PRALIMAP-CINeCO: Comparison of Health E-coaching Versus Referral to the Usual Care System

PRALIMAP-CINeCO: Comparison of Health E-coaching Versus Referral to the Usual Care System

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study involves young adults from the PRALIMAP-INES trial and student volunteers from the University of Lorraine, who are overweight or obese.

For young adults from the PRALIMAP-INES trial, the proposed research is a continuation of the PRALIMAP-CINeCO research (part 1).

For students at the University of Lorraine, the proposed research is aimed at volunteer students who are overweight or obese, via the University of Lorraine's Student Health Service (SSE).

Young adults and overweight or obese students not receiving medical care at the time of the inclusion visit (4th measurement time for PRALIMAP-INES participants and 1st time for others) will be offered the chance to take part in a randomized trial comparing the acceptability of health e-coaching versus referral to standard care.

Experimental group: health e-coaching Control group: usual care system

Primary objective : To determine the effectiveness of an e-health coaching intervention using new technologies that promotes changes in eating and physical activity behavior in overweight and obese young adults aged 20, an intervention targeting the development of autonomous self-regulation.

Secondary objectives :

  1. Determine the acceptability of health e-coaching: acceptability of new technologies (container), acceptability of personalized health e-coaching (content).
  2. Determine the effectiveness of health e-coaching on the criteria of corpulence (BMI; body composition), changes in eating behaviors (TCA), emotion management skills and social interaction skills.
  3. Evaluate the benefit of health e-coaching alone or combined with the previous intervention received in the PRALIMAP-INÈS trial on primary and secondary endpoints.
  4. Evaluate and compare participation in a health promotion program over two life periods (adolescence and young adulthood) for young adults from the PRALIMAP-INÈS trial.
  5. Evaluate the effectiveness of health e-coaching (reinforcement of autonomous self-regulation and changes in eating behaviors and physical activity practices/time spent sitting) according to the dose of intervention received by young adults (received-treatment analysis).
  6. Determine the cost-efficiency and cost-utility ratios by means of a medico-economic evaluation based on the incremental cost of the e-coaching intervention in relation to the usual care offered by the health care system (ICER: Incremental Cost-Effectiveness Ratio).

Eligibility

Inclusion Criteria:

        Among the young adults who agreed to participate in follow-up visit (T3) in the
        PRALIMAP-CINeCO trial (Part 1), the inclusion criteria for the inclusion criteria for the
        proposed research are as follows:
          -  Person having received complete information on the organization of the research and
             not and who did not object to their participation and to the use of their data to
             participate and to use their data
          -  Have agreed to complete the pre-test questionnaire prior to/at the follow-up visit
             (T3)
          -  Have agreed to the anthropometric measurements without invasive intervention performed
             at the follow-up visit (Q3)
          -  Have a BMI greater than 25kg/m² (Cole et al. 2000) or a percentage of body fat mass
             greater than or equal to 20% for men and greater than or equal to 33% for women,
             depending on age and greater than or equal to 33% for women and not receiving medical
             medical care for this situation
          -  Agree to participate in the follow-up
          -  Accepting the health e-coaching/orientation to routine care
          -  Affiliated to a social security system or beneficiary of such a system
          -  Reside in France
        Among the students who agreed to participate, through the Student Health Service of the
        University of Lorraine, the inclusion criteria for the proposed research are as follows:
          -  Person having received complete information on the organization of the research and
             not and who did not object to their participation and to the use of their data to
             participate and to use their data
          -  Have agreed to complete the pre-test questionnaire prior to/at the follow-up visit
             (T0)
          -  Have agreed to the anthropometric measurements without invasive intervention performed
             at the follow-up visit (T0)
          -  Have a BMI greater than 25kg/m² (Cole et al. 2000) or a percentage of body fat mass
             greater than or equal to 20% for men and greater than or equal to 33% for women,
             depending on age and greater than or equal to 33% for women and not receiving medical
             medical care for this situation
          -  Agree to participate in the follow-up
          -  Accepting the health e-coaching/orientation to routine care
          -  Affiliated to a social security system or beneficiary of such a system
          -  Reside in France
          -  Be of legal age (18 years or older)
          -  Be a student at the Université de Lorraine
        Exclusion Criteria:
        If the follow-up visit n°3 (T3) during the PRALIMAP-CINeCO trial (1st part) or the
        inclusion visit (T0 for University of Lorraine students), was completed, the non-inclusion
        criteria for the referral of young adults young adults (health e-coaching/current care) are
        as follows:
          -  Do not feel the need for coaching
          -  Be already being treated for overweight by a health professional specializing in the
             treatment of specialized in the treatment of overweight and obesity or a specialized
             specialized medical structure/service
          -  Do not agree to participate in the continuation of PRALIMAP-CINeCO
          -  Major person under a legal protection measure (guardianship, curatorship, safeguard of
             justice)
          -  Persons deprived of liberty by a judicial or administrative decision administrative
             decision Persons under psychiatric care in accordance with Articles L. 3212-1 and L.
             3213-1 of the Public Health Code

Study details
    Overweight and Obesity

NCT05399407

Central Hospital, Nancy, France

28 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.